Stasi Roberto
Regina Apostolorum Hospital, Department of Medical Sciences, Via S. Francesco, 50, 00041 Albano Laziale, Italy.
Expert Opin Biol Ther. 2008 Apr;8(4):527-40. doi: 10.1517/14712598.8.4.527.
Gemtuzumab ozogamicin consists of a semisynthetic derivative of calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal antibody.
To describe the pharmacology of gemtuzumab ozogamicin and to provide an overview of clinical trials in acute myeloid leukaemia.
Review and summary of publications on gemtuzumab ozogamicin indexed in the PubMed electronic database.
RESULTS/CONCLUSIONS: Gemtuzumab ozogamicin has shown moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myeloid leukaemia, with more promising results in acute promyelocytic leukaemia. The side effect profile may be an improvement on conventional chemotherapy, except for a higher frequency of veno-occlusive disease or sinusoidal obstructive syndrome, especially after a subsequent haematopoietic stem cell transplantation. Because of the different mechanisms of action and non-overlapping toxicities, the integration of this immunoconjugate with standard chemotherapy is a rational approach, and Phase III trials are ongoing both in the induction and in the post-remission settings.
吉妥珠单抗奥唑米星由刺孢霉素的半合成衍生物组成，刺孢霉素是一种强效细胞毒性抗生素，与一种人源化抗CD33单克隆抗体相连。
描述吉妥珠单抗奥唑米星的药理学，并概述急性髓系白血病的临床试验。
回顾和总结PubMed电子数据库中索引的关于吉妥珠单抗奥唑米星的出版物。
结果/结论：吉妥珠单抗奥唑米星作为单一药物在CD33阳性难治性或复发性急性髓系白血病患者中显示出中等活性，在急性早幼粒细胞白血病中结果更有前景。除了静脉闭塞性疾病或窦性阻塞综合征的发生率较高外，尤其是在随后的造血干细胞移植后，其副作用可能优于传统化疗。由于作用机制不同且毒性不重叠，将这种免疫缀合物与标准化疗相结合是一种合理的方法，诱导期和缓解后阶段的III期试验正在进行。
